Literature DB >> 26283446

Longitudinal Andhra Pradesh Eye Disease Study: rationale, study design and research methodology.

Rohit C Khanna1,2, Gudlavalleti Vs Murthy3,4, Srinivas Marmamula1,2, Asha Latha Mettla1,2, Pyda Giridhar1,2, Seema Banerjee1,2, Konegari Shekhar1,2, Subhabrata Chakrabarti2, Clare Gilbert3, Gullapalli N Rao1,2.   

Abstract

BACKGROUND: The rationale, objectives, study design and procedures for the longitudinal Andhra Pradesh Eye Disease Study are described.
DESIGN: A longitudinal cohort study was carried out. PARTICIPANTS: Participants include surviving cohort from the rural component of Andhra Pradesh Eye Disease Study.
METHODS: During 1996-2000, Andhra Pradesh Eye Disease Survey was conducted in three rural (n = 7771) and one urban (n = 2522) areas (now called Andhra Pradesh Eye Disease Study 1). In 2009-2010, a feasibility exercise (Andhra Pradesh Eye Disease Study 2) for a longitudinal study (Andhra Pradesh Eye Disease Study 3) was undertaken in the rural clusters only, as urban clusters no longer existed. In Andhra Pradesh Eye Disease Study 3, a detailed interview will be carried out to collect data on sociodemographic factors, ocular and systemic history, risk factors, visual function, knowledge of eye diseases and barriers to accessing services. All participants will also undergo a comprehensive eye examination including photography of lens, optic disc and retina, Optic Coherence Tomography of the posterior segment, anthropometry, blood pressure and frailty measures. MAIN OUTCOME MEASURES: Measures include estimates of the incidence of visual impairment and age-related eye disease (lens opacities, glaucoma and age-related macular degeneration) and the progression of eye disease (lens opacities and myopia) and associated risk factors.
RESULTS: Of the 7771 respondents examined in rural areas in Andhra Pradesh Eye Disease Study 1, 5447 (70.1%) participants were traced in Andhra Pradesh Eye Disease Study 2. These participants will be re-examined.
CONCLUSIONS: Andhra Pradesh Eye Disease Study 3 will provide data on the incidence and progression of visual impairment and major eye diseases and their associated risk factors in India. The study will provide further evidence to aid planning eye care services.
© 2015 Royal Australian and New Zealand College of Ophthalmologists.

Entities:  

Keywords:  Andhra Pradesh Eye Disease Study; cohort; incidence; progression; risk factors

Mesh:

Year:  2015        PMID: 26283446     DOI: 10.1111/ceo.12633

Source DB:  PubMed          Journal:  Clin Exp Ophthalmol        ISSN: 1442-6404            Impact factor:   4.207


  5 in total

1.  Angiopoietin receptor TEK interacts with CYP1B1 in primary congenital glaucoma.

Authors:  Meha Kabra; Wei Zhang; Sonika Rathi; Anil K Mandal; Sirisha Senthil; Goutham Pyatla; Muralidhar Ramappa; Seema Banerjee; Konegari Shekhar; Srinivas Marmamula; Asha L Mettla; Inderjeet Kaur; Rohit C Khanna; Hemant Khanna; Subhabrata Chakrabarti
Journal:  Hum Genet       Date:  2017-06-15       Impact factor: 4.132

2.  Utilization of eye care services among those with unilateral visual impairment in rural South India: Andhra Pradesh Eye Disease Study (APEDS).

Authors:  Srinivas Marmamula; Pyda Giridhar; Rohit C Khanna
Journal:  Int J Ophthalmol       Date:  2017-03-18       Impact factor: 1.779

3.  The Jidong Eye Cohort Study: objectives, design, and baseline characteristics.

Authors:  Kai Yang; Lele Cui; Guoyun Zhang; Xianwei Wang; Xiaoxuan Zhu; Yunfan Xiao; Binbin Su; Daiyu Song; Xinyao Zhang; Yang Zheng; Fan Lu; Jia Qu; Ming Li
Journal:  Eye Vis (Lond)       Date:  2020-12-29

4.  Awareness of cataract and glaucoma in two rural districts of Telangana, India.

Authors:  Srinivas Marmamula; Dharani Boopalan; Rohit C Khanna; Neha Hassija; Jill Keeffe
Journal:  Indian J Ophthalmol       Date:  2022-03       Impact factor: 2.969

5.  Associations of grip strength with retinal and choroidal thickness in patients with type 2 diabetes mellitus without retinopathy: a cross-sectional study.

Authors:  Zihan Qiu; Wei Wang; Yan Tan; Miao He; Langhua Wang; Yuting Li; Xia Gong; Wenyong Huang
Journal:  BMJ Open       Date:  2020-07-19       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.